API Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (Websockets) API Financial News API Delisted Data API
Solutions
New & Popular APIs
Show all APIs Fundamental Data APIs Indices Historical Constituents API 40 000 Stock Market Logos API Forex Data APIs
Other products
Google Sheets Add-on Excel Add-on Coding Libraries (Python, R, etc) Wordpress Add-on
API Marketplace
Community
Academy 134 articles Forum Github 13 repos
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. LSE /
  3. EKF.LSE

EKF Diagnostics Holdings Plc (EKF LSE) stock market data APIs

p29.3 0.65(2.3%) as of September 10, 2024
Price chart is built with Anychart

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; Ultracrit, a hematocrit device; DiaSpect Hemoglobin T analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, a breast milk analyzer; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company provides clinical chemical analyzers, such as Beta-hydroxybutyrate for monitoring ketosis; Glycated Albumin; Glycated Serum Protein; Nitro-tab Ketone tablets; and Procalcitonin marker for bacterial infection and sepsis, as well as reagents, calibrators, standards, and controls. Additionally, it offers RaPET Serology immunoassay kits; QuStick Strep A for Strep A infection treatment; Altair 240 and Excel analyzers; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; and kits and other services related to COVID-19, as well as contract manufacturing solutions to third-parties. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

EKF Diagnostics Holdings Plc Financial Data Overview

28.65
29.3
-
29.3
27.5
23-34
127 M
27.95
454 M
52 611 K
-0.03
0.0465
0.57
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'EKF',
Type: 'Common Stock',
Name: 'EKF Diagnostics Holdings Plc',
Exchange: 'LSE',
CurrencyCode: 'GBX',
CurrencyName: 'Pence sterling',
CurrencySymbol: 'p',
CountryName: 'UK',
CountryISO: 'GB',
OpenFigi: NULL,
ISIN: 'GB0031509804',
CIK: NULL,
EmployerIdNumber: '',
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: 'International',
Sector: 'Healthcare',
Industry: 'Medical Devices',
}

EKF Diagnostics Holdings Plc Fundamental Data is available in our Financial Data APIs

  • Net Revenue 52 611 K
  • EBITDA 9 254 K
  • Earnings Per Share 0.01
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get EKF Diagnostics Holdings Plc Earnings via APIs

  • Latest Release 2023-03-28
  • EPS/Forecast 0.89

Get EKF Diagnostics Holdings Plc End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get EKF Diagnostics Holdings Plc latest news via APIs

Shareholders in EKF Diagnostics Holdings (LON:EKF) are in the red if they invested three years ago

Many investors define successful investing as beating the market average over the long term. But in any portfolio, there are likely to be some stocks that fall short of that benchmark. Unfortunately, ...

EKF Diagnostics Holdings Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags

EKF Diagnostics Holdings (LON:EKF) Full Year 2022 Results Key Financial Results Revenue: UK£66.6m (down 19% from FY 2021). Net loss: UK£10.1m (down by 164% from UK£15.9m profit in FY 2021). UK£0...
Do you have any questions?
support@eodhistoricaldata.com